Supreme Court Justices Support FDA's Authority To Remedy Fraud Claims
This article was originally published in The Gray Sheet
Executive Summary
Supreme Court Justice Stephen Breyer's comments supporting broad enforcement flexibility for FDA during oral arguments in The Buckman Co. v Plaintiffs' Legal Committee are consistent with his concurring opinion in the 1996 case Medtronic v. Lohr.
You may also be interested in...
Supreme Court Questions Whether 510(k) "Intended Use" Must Be Bona Fide
The "intended use" statement in a 510(k) is "not a factual representation" of how a device will be used on the market, Kenneth Geller, attorney for the Buckman Co., contended before the U.S. Supreme Court Dec. 4.
Sanofi Clinches Key Phase III Immunology Win With Rilzabrutinib
Sanofi’s BTK inhibitor – one of two from its 2021 Principia buy – passed a Phase III test in immune thrombocytopenia as the company focuses on Dupixent-like blockbusters going forward.